Scalable, Metal- and Additive-Free, Photoinduced Borylation of Haloarenes and Quaternary Arylammonium Salts

We report herein a simple, metal- and additive-free, photoinduced borylation of haloarenes, including electron-rich fluoroarenes, as well as arylammonium salts directly to boronic acids. This borylation method has a broad scope and functional group tolerance. We show that it can be further extended to boronic esters and carried out on gram scale as well as under flow conditions

Additive- and Metal-Free, Predictably 1,2- and 1,3-Regioselective, Photoinduced Dual C–H/C–X Borylation of Haloarenes

We report herein a simple, additive- and metal-free, photoinduced, dual C–H/C–X borylation of chloro-, bromo-, and iodoarenes. The reaction produces 1,2- and 1,3-diborylarenes on gram scales under batch and continuous flow conditions. The regioselectivity of the dual C–H/C–X borylation is determined by the solvent and the substituents in the parent haloarenes

Additive- and Metal-Free, Predictably 1,2- and 1,3-Regioselective, Photoinduced Dual C–H/C–X Borylation of Haloarenes

We report herein a simple, additive- and metal-free, photoinduced, dual C–H/C–X borylation of chloro-, bromo-, and iodoarenes. The reaction produces 1,2- and 1,3-diborylarenes on gram scales under batch and continuous flow conditions. The regioselectivity of the dual C–H/C–X borylation is determined by the solvent and the substituents in the parent haloarenes

Demographic characteristics of whole cohort.

<p>Abbreviations: ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ATG: anti-thymocyte globulin; Bu: busulfan; Cy: cyclophosphamide; CR: Complete remission; Flu: fludarabine; MDS: myelodisplastic syndrome; Mel: melphalan; MMU: mismatch unrelated; MRD: matched related donor; MTX: methotrexate; MUD: matched unrelated donor; VP16: etoposide.</p

Cumulative incidence of neutrophil and platelets recovery.

<p>A) 69.3% (95%CI: 58.49–80.11%) of patients positive for both class I and II anti HLA antibodies (AHA) had neutrophil recovery (NR) compared to 89.3% of negative patients (95% CI: 82.06–96.54%). NR did not differed in both groups, Gray’s test p-value = 0.21, hazards ratio is 1.6 (0.8–3.3). No patients detected for both class AHA were dead before NR. B) Patient’s positive for anti major-histocompatibility-complex class I–related chain A antigen (MICA) antibodies had lower cumulative incidences of platelet recovery (PR, 26.5% (95% CI: 15.51–37.49%) compared to negative patients (80.5%; 95% CI: 70.64–90.36%).Total number of patients included in analysis was 62; death before PR was used as competing event, and for 8 patients we do not have conclusive MICA status. Gray’s test p value = 0.04, hazards ratio is 4.3 (1.02–17.8).</p